The number of subcutaneous adipocytes wherein fat can be stored during adulthood is essentially determined in two windows of adipogenesis, namely, fetal life and puberty ([@B1],[@B2]). For example, in monozygotic twins discordant for growth before birth, the smaller twin continues to have a lower number of subcutaneous adipocytes after birth ([@B3]). It is still poorly understood how a transient restraint of fetal growth can be linked to a persistent lowering of adipocyte number. We propounded that one of the potential links is a downregulation of adipogenesis in a critical window of growth restraint before birth. In a first test of this concept, we studied at birth whether circulating preadipocyte factor 1 (Pref-1) is higher in smaller fetuses. Pref-1 is a transmembrane protein that is encoded by an imprinted (paternally expressed) gene on chromosome 14q32 and that contains an extracellular domain with epidermal growth factor--like repeats; juxtamembrane cleavage generates a soluble 50-kDa form, which is the Pref-1 form that inhibits adipocyte differentiation by upregulating Sox9 in preadipocytes ([@B4],[@B5]). Thus far, the circulating levels of Pref-1 have not been studied in human fetuses, newborns, infants, or pregnant women.

RESEARCH DESIGN AND METHODS {#s2}
===========================

Pref-1 was measured longitudinally (at birth and at 4 months) in serum from 72 infants (42 born appropriate for gestational age \[AGA\] \[19 girls and 23 boys\] and 30 born small for gestational age \[SGA\] \[16 girls and 14 boys\]) who had been recruited into a study that was initiated in 2007 and that assesses longitudinally the endocrine-metabolic state and the body composition of SGA infants compared with breastfed AGA control subjects across the first postnatal years ([@B6],[@B7]). For the present substudy focusing on Pref-1, specific inclusion criteria were as follows: *1*) birth at Hospital Sant Joan de Déu after an uncomplicated, term (38--40 weeks), and singleton pregnancy (no maternal hypertension and no gestational diabetes); *2*) birth weight between 3.0 and 3.8 kg for AGA control subjects (birth weight range between −1 and +1 SD), and birth weight \<2.6 kg for SGA infants (below −2 SD); *3*) cord serum available to measure Pref-1; and *4*) written informed consent in the Catalan language. Specific exclusion criteria were complications at birth (need for resuscitation or for parenteral nutrition), congenital malformations, or an extremely low birth weight (below −3.0 SD).

Gestational age was calculated according to the last menses and confirmed by first-trimester ultrasound. The prevalence of delivery by caesarean section was 12%. A total of 17 mothers smoked during pregnancy; they delivered 7 AGA and 10 SGA infants.

Pref-1 was also measured in 11 healthy AGA newborns (mean birth weight 3.3 kg) sampled on postnatal day 2 or 3 (mean age 44 h \[range 30--57\]) and from 18 women in late gestation (mean 35 weeks \[32--38\]) who subsequently delivered healthy infants (mean birth weight 3.3 kg \[2.7--4.0\]) after uncomplicated singleton pregnancies (mean duration 39 weeks \[37--41\]).

Body weight was measured at birth with a beam balance (Seca, Hamburg, Germany). Blood from the longitudinally studied infants was sampled at birth (from the umbilical cord before placental separation) and in the prefeeding state at age 4 months. All samples were centrifuged and frozen at −80°C until analysis. Body composition was assessed by absorptiometry at age 2 weeks (mean ± SEM 17 ± 1 days) with a Lunar Prodigy, coupled to Lunar software (version 3.4/3.5; Lunar, Madison, WI) adapted for infants ([@B6],[@B7]). Soluble 50-kDa Pref-1 was assessed by ELISA (R&D Systems, Minneapolis, MN) (intra- and interassay coefficients of variation 3.6 and 6.2%, respectively; detection limit 0.01 μg/L).

Statistical analyses were performed using SPSS 12.0 (SPSS, Chicago, IL). Results are expressed as means ± SEM. Comparisons between groups were performed by *t* test. Skewed data were log transformed prior to comparison. *P* \< 0.05 was considered significant.

All assessments were approved by the institutional review board of Barcelona University Hospital. Written (parental) consent was an inclusion criterion.

RESULTS {#s3}
=======

Pref-1 levels in late-gestational women were 0.7 ± 0.1 μg/L (range 0.02--1.6), which were comparable with those reported in nonpregnant women ([@B8]). Circulating Pref-1 was readily detectable in all infants. Pref-1 levels were comparable in girls and boys, and the results of both sexes were therefore pooled ([Table 1](#T1){ref-type="table"}).

###### 

Results from AGA versus SGA infants
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At birth, Pref-1 levels ranged from 6 to 100 μg/L and were thus one to two orders of magnitude higher than in the maternal circulation. Pref-1 levels were \~50% higher in SGA than in AGA fetuses. By age 4 months, Pref-1 concentrations had reached a near-adult level and the original AGA versus SGA difference in Pref-1 levels had disappeared. No close associations were observed between Pref-1 concentrations and body composition either at birth or at age 4 months. On day 2 or 3, serum concentrations of Pref-1 in AGA newborns were still 14 ± 2 μg/L (range 8--26), suggesting that prenatal Pref-1 has a fetal rather than a placental or maternal origin.

CONCLUSIONS {#s4}
===========

In the first months after birth, SGA infants prioritize the recovery of lean mass to that of fat mass and of bone mineral content. Soluble Pref-1 is thought to reduce adipogenesis as well as bone formation by inhibiting the differentiation of multipotent mesenchymal cells into adipocytes, chondrocytes, and osteoblasts ([@B5],[@B9],[@B10]). Here, we show that Pref-1 is abundantly present in the circulation of the human fetus and that SGA fetuses have higher Pref-1 levels than do AGA control subjects.

Growth restraint in early life is a major risk factor for diabetes in later life ([@B11],[@B12]). Our finding that fetal growth restraint is associated with markedly high Pref-1 levels suggests that Pref-1 may be among the mediators of a reduced adipocyte differentiation in growth-restrained fetuses, and thus of a reduction in their life-long lipid-storage capacity and also of their adult vulnerability to metabolic disease, once lipid storage becomes an issue.

In conclusion, Pref-1 is abundantly present in the circulation of the human fetus and is likely to be of fetal rather than maternal or placental origin. Circulating Pref-1 levels are higher in SGA than in AGA fetuses.
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